Pfizer will relinquish its stake in ViiV Healthcare in a deal valued at just over $2.1 billion that ramps up Shionogi's ...
Powerful new weight-loss medications are in the works to treat obesity. Doctors explain why more options are needed and the ...
GSK has agreed to pay $58 per RAPT share, with an upfront payment of $1.9 billion, that will give it global rights to ...
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call ...
Zacks Investment Research on MSN
BMY vs GSK: Which biopharma giant has better prospects for now?
Bristol Myers Squibb BMY and GSK PLC GSK are among the largest global biopharma companies with broad and diverse portfolios.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback